|Videos|January 18, 2023

The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer

Author(s)Stephen J. Freedland, MD

Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.

Episodes in this series

EP. 1 Case Presentation: A 67-Year-Old-Man with Metastatic Prostate Cancer

EP. 1 Case Presentation: A 67-Year-Old-Man with Metastatic Prostate Cancer

EP. 2 Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP. 2 Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP. 3 Factors for Consideration When Selecting Treatments for Patients with mCRPC

EP. 3 Factors for Consideration When Selecting Treatments for Patients with mCRPC

EP. 4 The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer

EP. 4 The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer

EP. 5 Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

EP. 5 Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPC

ByHannah Clarke

August 10th 2026

The AUA Clinically Localized Prostate Cancer guideline: FAQs for urologists

ByHannah Clarke

August 10th 2026

Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC

ByHannah Clarke

August 8th 2026

Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer

ByNeil H. Baum, MD,Abraham Morgentaler, MD

August 6th 2026

FDA updates in urology: July 2026

ByHannah Clarke

August 4th 2026

Latest CME

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPC

Jessica Yih, MD, highlights data on testosterone therapy in women

Blue light cystoscopy is tied to higher resource use, not health care cost, in NMIBC

The AUA Clinically Localized Prostate Cancer guideline: FAQs for urologists

Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC